Dysregulated expression of EGFR and its encoded receptor tyrosine kinase activity may lead to the induction of various cancerous cellular processes underlying the LC pathology, making it a key target of widely used antitumor agents against LC in clinical settings [87–89]. Here, EGFR is linked to laryngotracheoesophageal cleft.